A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate of watch-and-wait patients was not inferior to that o ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Use of certain cancer drugs declines significantly after the emergence of negative confirmatory trial data, even though the medications remain available through off-label use.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...